Project Grant R01CA279689
- This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is funding research at Yale University to investigate the role of the enzyme TENT2 in regulating microRNA-1 (miR-1) degradation in tumor endothelial cells (TECs) and its impact on tumor angiogenesis and progression in non-small cell lung cancer (NSCLC). The $430,684 award, which runs from July 2024 to June 2026, will support two specific aims: 1) determining the role of TENT2 in...
- Federal Project Grant Award Summary The National Cancer Institute awarded Massachusetts General Hospital a $416,818 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for the period August 1, 2025 through July 31, 2027. The award supports preclinical research investigating whether physical activity enhances Chimeric Antigen Receptor (CAR)-T cell immunotherapy effectiveness in metastatic breast cancer by normalizing the tumor microenvironment. The research will employ...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Emory University a $156,500 Project Grant on August 1, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct integrated multi-omics research exploring the pathophysiology of cachexia in head and neck squamous cell carcinoma (HNSCC) patients. The two-year project, concluding July 31, 2027, will investigate the systemic biological mechanisms underlying cancer cachexia through comprehensive analysis of...
- Federal Project Grant Award Summary The National Cancer Institute awarded Indiana University Indianapolis a $423,084 Project Grant under the Cancer Biology Research program (CFDA 93.396) to investigate the musculoskeletal wasting syndrome associated with metastatic colorectal cancer. The research project, initiated May 5, 2025 and extending through April 30, 2030, focuses on identifying the biological mechanisms by which cancer cachexia—a multi-organ wasting condition responsible for over 30% of...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $157,980 to Loyola University of Chicago on August 8, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support Dr. Jonathan Rennhack's research on colorectal cancer (CRC) metastasis. The project, which extends through July 31, 2028, focuses on unraveling the role of microenvironmental chemokines in beta-catenin/T-cell factor (TCF) signaling during CRC metastasis to the liver and lung. Dr. Rennhack...
- Grant Award Summary The Medical College of Wisconsin, Inc. received a $494,160 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective September 11, 2025, with a completion date of August 31, 2030. This five-year research project investigates the role of extracellular vesicle (EV)-loaded FXR1 messenger RNA (mRNA) in remodeling the tumor microenvironment in ovarian cancer. The research focuses on characterizing how fragile...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $708,990 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2031. The grant supports fundamental research investigating the microenvironmental and hepatocyte cell type-specific regulation of colorectal cancer (CRC) metastasis by the IL17 cytokine. The research aims to elucidate how IL17 signaling in hepatocytes and myeloid...
- This $408,599 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the TGF-beta/SMAD3 pathway in endothelial damage and cardiac remodeling caused by doxorubicin chemotherapy. The research aims to assess how doxorubicin-induced endothelial reprogramming via this pathway contributes to the development of cardiomyopathy, and whether suppressing SMAD3...
- The National Science Foundation (NSF) awarded a $437,038 Project Grant under the Engineering program (CFDA 47.041) to the University of Massachusetts (UMass) to develop a technology for targeted electrical stimulation of endothelial cells lining blood vessels. The objective is to modulate endothelial cell function to enhance drug delivery to tumors and improve treatment outcomes for cancer patients. The 5-year project will study pulsed electric field waveforms that can selectively alter...
REWIRING CANCER-INDUCED ABNORMALITIES IN THE VASCULAR BARRIER - SUMMARY TUMORS ARE KNOWN TO INDUCE THE FORMATION OF UNIQUE MICROENVIRONMENTS IN DISTANT ORGANS THAT FACILITATE SEEDING, SURVIVAL, AND GROWTH OF METASTATIC NODULES. THESE SITES, KNOWN AS PRE- METASTATIC NICHES, EMERGE AS A RESPONSE TO THE COMBINED SYSTEMIC EFFECTS OF TUMOR-DERIVED FACTORS AND SHED EXTRACELLULAR VESICLES. ASIDE FROM PREMETASTATIC NICHES, DISTANT ALTERATIONS IN OTHERWISE NORMAL TISSUES OF CANCER-BEARING SUBJECTS HAVE NOT BEEN IDENTIFIED. WHILE EVALUATING THE SYSTEMIC VASCULATURE OF TUMOR-BEARING MICE, WE SERENDIPITOUSLY FOUND THAT PRESENCE OF CERTAIN TYPES OF CARCINOMAS IMPLANTED SUBCUTANEOUSLY HAVE A DELETERIOUS EFFECT ON INTESTINAL LYMPHATICS AND BLOOD VESSELS. THIS SURPRISING FINDING WAS DIRECTLY CORRELATED WITH SEVERE WEIGHT LOSS AND PROGRESSIVE REDUCTION OF SKELETAL MUSCLE MASS, A CONDITION KNOWN AS CACHEXIA. IMPORTANTLY, IN CANCER PATIENTS, CACHEXIA HAS A MEANINGFUL NEGATIVE IMPACT IN THEIR ABILITY TO RESPOND AND RECOVER FROM THERAPY AND THUS IDENTIFICATION OF INDIVIDUALS AT RISK AND EFFECTIVE TREATMENTS TO REVERSE THIS CONDITION ARE IMPERATIVE. BLOCKING CACHEXIA OFFERS NOT ONLY A SIGNIFICANT IMPROVEMENT IN THE QUALITY OF LIFE FOR THESE PATIENTS, BUT IT ALSO IMPROVES TOLERANCE AND RESPONSE TO CANCER TREATMENT, WITH MEASURABLE INCREASE IN SURVIVAL RATES. ALTHOUGH THE CLINICAL CONSEQUENCES OF CACHEXIA AND ITS POSITIVE RESPONSE TO THERAPY ARE WELL KNOWN, READ- OUTS FOR EARLY DIAGNOSIS AND EFFECTIVE TREATMENT REMAIN CHALLENGING. OUR PRELIMINARY FINDINGS UNCOVERED THAT TUMORS WITH HIGH CIRCULATING LEVELS OF SPECIFIC INFLAMMATORY CYTOKINES INDUCED VASCULAR AND LYMPHATIC BARRIER DYSFUNCTION IN THE INTESTINE. IN PARTICULAR, THE CAPILLARIES AND CENTRAL LYMPHATIC LACTEAL OF INTESTINAL VILLI SHOWED PROLONGED AND EXACERBATED LEVELS OF VEGFR2/3 SIGNALING, TAK1 PHOSPHORYLATION AND OTHER ALTERATIONS THAT YIELD COMPROMISED JUNCTIONAL COMPLEXES. IN TURN, WE DOCUMENTED CHANGES IN FOOD ABSORPTION DESPITE UNALTERED LEVELS OF FOOD CONSUMPTION AND ASSOCIATED WEIGHT LOSS. COLLECTIVELY, THE FINDINGS INDICATE THAT CANCER-INDUCED ALTERATIONS IN THE VASCULO-LYMPHATIC COMPARTMENT OF INTESTINAL VILLI CONTRIBUTE TO, AND PERHAPS TRIGGER, THE DEVELOPMENT OF CACHEXIA BY AFFECTING THEIR ABILITY TO ABSORB LIPIDS. THE GOAL OF THIS PROJECT IS TO DETERMINE WHETHER DEFICIENCIES IN LYMPHATIC AND VASCULAR ENDOTHELIUM ARE A SIGNIFICANT UNDERLYING CAUSE OF CANCER-INDUCED CACHEXIA THAT CAN BE TARGETED TO REVERSE THE CONDITION. OUR TWO PROGUED APPROACH WILL DELVE INTO FURTHER UNDERSTANDING OF THE UNDERLYING MOLECULAR MECHANISMS WHILE PURSUING PRE-CLINICAL TRIALS IN MOUSE MODELS TO TEST THERAPEUTIC AVENUES AIMED AT CORRECTING THE VASCULAR DEFICIENCIES. THE CONTRIBUTION OF THE VASCULATURE AS AN IMPORTANT CULPRIT IN CACHEXIA HAS NOT BEEN RECOGNIZED AND IT COULD BE TRANSFORMATIVE AS IT MAY OFFER AN UNPRECEDENTED OPPORTUNITY FOR INTERVENTION AT EARLY STAGES BY FOCUSING ON REWIRING ENDOTHELIAL BARRIER AND BLOCKING THIS DEVASTATING CONDITION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $523.0k | 7/8/25 | ||
| Not listed | $502.6k | 7/3/24 |